Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Accounting for age of onset and family history improves power in genome-wide association studies

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Leveraging both individual-level genetic data and GWAS summary statistics increases polygenic prediction

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Genome-wide association studies (GWASs) have revolutionized human genetics, allowing researchers to identify thousands of disease-related genes and possible drug targets. However, case-control status does not account for the fact that not all controls may have lived through their period of risk for the disorder of interest. This can be quantified by examining the age-of-onset distribution and the age of the controls or the age of onset for cases. The age-of-onset distribution may also depend on information such as sex and birth year. In addition, family history is not routinely included in the assessment of control status. Here, we present LT-FH++, an extension of the liability threshold model conditioned on family history (LT-FH), which jointly accounts for age of onset and sex as well as family history. Using simulations, we show that, when family history and the age-of-onset distribution are available, the proposed approach yields statistically significant power gains over LT-FH and large power gains over genome-wide association study by proxy (GWAX). We applied our method to four psychiatric disorders available in the iPSYCH data and to mortality in the UK Biobank and found 20 genome-wide significant associations with LT-FH++, compared to ten for LT-FH and eight for a standard case-control GWAS. As more genetic data with linked electronic health records become available to researchers, we expect methods that account for additional health information, such as LT-FH++, to become even more beneficial.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Human Genetics
Vol/bind109
Udgave nummer3
Sider (fra-til)417-432
Antal sider16
ISSN0002-9297
DOI
StatusUdgivet - 3 mar. 2022

Bibliografisk note

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

ID: 74463071